Introduction
Infection by HIV may result in a state of asymptomatic seropositivity, a variety of AIDS-related conditions (ARC),' or AIDS (1) . In the natural course of HIV infection, most individuals will ultimately develop ARC or AIDS (2) . Cytopathic or inhibitory effects of HIV on T cells and macrophages that express the CD4 differentiation antigen play a central role in many of the immunological defects of HIV-infected individuals (3) (4) (5) (6) (7) (8) (9) . The progressive accumulation of these defects in HIV-infected patients permits the development of infectious and neoplastic diseases.
The immune system does not passively accept these insults that are inflicted by HIV, but produces specific antibodies and 1. Abbreviations used in this paper: Ab+, antibody positive; Ab-, antibody negative; ARC, AIDS-related conditions; CMV, cytomegalovirus; gpl2O, 120-kD envelope glycoprotein of HIV; rIL-2, recombinant IL-2; SI, stimulation index of proliferation; TT, tetanus toxoid; X, mean. cell-mediated responses in an attempt to control this virus (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . Both proliferative and cytotoxic lymphocyte responses to products of the gag, pol, or env genes of HIV have been reported (9, 15, 16, 18, 19) . Very little is known, however, of the roles of adaptive immune responses, particularly of cellmediated responses to specific HIV antigens, in controlling the pathogenesis of HIV infections. Cell-mediated immunity appears to be important in controlling other types of viral infections (20) (21) (22) , suggesting that some of these types of responses may also be beneficial to HIV-infected individuals.
The studies described in this report characterize lymphocyte proliferation in response to purified HIV and its subunits as an index of cell-mediated immune responses in HIV-infected individuals. As an extension of our previous studies demonstrating the immunosuppressive properties of HIV or its subunits in vitro (5) , the nonglycosylated ENV2-3 and core (p25) recombinant proteins of HIV (10, 11, 14) were also tested for their ability to inhibit antigen-and mitogen-driven lymphocyte proliferation. Additional analysis to elucidate the effects of HIV-antigens on cell-mediated immune responses hopefully will facilitate manipulation of these responses to prevent or treat HIV infections.
Methods
Study subjects. Asymptomatic HIV seronegative (Ab-) and HIV seropositive (Ab+) males were hospital personnel and homosexual men participating in an epidemiologic study of AIDS (2) (12, 13) . Phenotypic analysis of CD4+ and CD8+ lymphocytes was performed as described (5) .
Antigens and mitogens. The HIV-SF2 isolate (23) of HIV-1 was purified from supernatants of persistently infected HUT-78 cells as described previously (24) . This purified virus and concentrated supernatants of uninfected HUT-78 cells were treated for 30 min at 560C. Protein concentrations were determined by absorbance at 280 nm using BSA as a standard. Recombinant p25 protein of HIV-SF2 was expressed in Escherichia coli and purified as described (10) . Recombinant envelope proteins of HIV-SF2 were expressed in Saccharomyces cerevisiae and purified as described (1 1 (5) . Units of IL-2 were quantitated by determining the dilution of rIL-2 that resulted in significant proliferation (P < 0.003) of IL-2-dependent CTLL cells (25) . After 20 gg/ml) of purified and inactivated HIV-SF2 or with supernatant proteins of uninfected HUT-78 cells that were used for HIV propagation. Parallel cultures also contained an optimal concentration of rIL-2 (5 U/ml). Lymphocytes from all eight HIV Ab-individuals failed to proliferate in response to any concentration of HIV-SF2 or HUT-78 supernatant proteins in either the presence or absence of rIL-2 ( Fig. 1 A) . Lymphocytes from only 1 of 10 HIV Ab+ asymptomatic individuals exhibited significant proliferative responses (P < 0.001 in comparison with HIV Ab-individuals) to HIV-SF2 (optimally at 10 Ag/ml) and this response was abrogated rather than augmented by the addition of rIL-2 ( Fig. 1 B) . This asymptomatic individual's lymphocytes also proliferated in response to HIV-SF2 in the absence of added rIL-2 but not in its presence when tested 1 50 ,g/ml, in both the pres- ence and absence of rIL-2, but failed to manifest significant proliferative responses (data not shown). Fig. 2 shows the results of Western blot analysis of the purified HIV-SF2 preparation used in these studies (Lane A) . Although variable amounts of gp 160 were present in different preparations, all major proteins characteristic of HIV including gp160, gpl20, gp41, p3 1, and p25 were present in the material used for these lymphocyte proliferation studies. (24) were subjected to Western analysis using sera from an 25 HIV Ab+ male (12 (Fig. 3 A) . Most HIV Ab-individuals' lymphocytes, however, proliferated optimally in both the presence and absence of rIL-2 when cultured with doses between 0.01 and 20 ,gg/ml ofa lysate ofE. coli, the organism used to express the recombinant p25 protein (10). Only 2 of 11 HIV Ab+ asymptomatic individuals' lymphocytes proliferated in response to p25 in the absence of rIL-2, and lymphocytes from these two and another individual proliferated when rIL-2 was added (Fig. 3 A) . Only 3 of 18 ARC patients' lymphocytes proliferated in response to p25 in the absence of rIL-2, and these responses were not augmented by the addition of rIL-2. Lymphocytes from one ARC patient proliferated in response to p25 in the presence ofrIL-2 but not in its absence (Fig. 3 A) . In the absence of rIL-2, lymphocytes from 5 of 11 HIV Ab+ asymptomatic individuals and 2 of 18 ARC patients proliferated in response to E. coli antigens (Fig. 3 B) . Unlike the responses to p25, the responses of lymphocytes from many HIV Ab+ individuals to E. coli were augmented by the addition of rIL-2 (Fig. 3 B) . In the presence of rIL-2, 8 of 11 (72.7%) HIV Ab+ asymptomatic individuals' and 14 of 18 (77.8%) ARC patients' lymphocytes proliferated in response to E. coli.
All 11 HIV Ab-individuals failed to exhibit lymphocyte proliferation in response to any concentration of recombinant ENV2-3 that contains the protein backbone of gpl20 (11) , either in the presence or in the absence of rIL-2 (Fig. 4) . Most HIV Ab-individuals' lymphocytes did, however, proliferate in response to a lysate of S. cerevisiae, which was used to express the recombinant ENV2-3 protein (11). 2 viduals' lymphocytes proliferated in response to ENV2-3 significantly in the presence of rIL-2. 2 of 13 ARC patients' lymphocytes proliferated in response to ENV2-3, but these responses were not augmented by the addition of rIL-2 (Fig. 4  A) . Similar to the responses of HIV Ab+ individuals to the E. coli lysate (Fig. 3 B) , proliferative responses of HIV Ab+ asymptomatic individuals' and ARC patients' lymphocytes to the S. cerevisiae lysate were often significantly augmented (P < 0.01) by the addition of rIL-2 (Fig. 4 B) . 
Discussion
Infection by viruses such as CMV or influenza characteristically induce lymphocytes capable of proliferating in vitro in response to the sensitizing viral antigens (5, 9, 21, 27) . These proliferative responses are generally associated with the activity of CD4+ helper T lymphocytes (4, 28) . In contrast to proliferative responses to other viruses, results presented in this report and elsewhere (9, 15, 29) demonstrate that many HIVinfected individuals' lymphocytes fail to multiply in primary cultures in response to antigens of HIV. The results presented in this report and elsewhere (15, 29) demonstrate that the poor proliferative responses to HIV antigens occur not only when the antigens ofHIV-SF2 are used for in vitro challenge but also in the presence of HTLV-III antigens. It is, therefore, unlikely that the defects observed in proliferative responses are merely due to polymorphism among proteins of divergent HIV-1 isolates, especially as many conserved regions of HIV envelope and core proteins are known to exist (30). The possibility that T cells or antibodies recognizing polymorphic determinants of HIV antigens may not effectively recognize divergent HIV isolates, however, is an important consideration in the development of effective prophylaxis and therapy for HIV infections.
The selective nature of proliferative defects is evident in many HIV-infected individuals whose lymphocytes are competent to respond to other "recall" antigens. Furthermore, proliferative responses ofHIV Ab+ asymptomatic individuals' and ARC patients' lymphocytes to other recall antigens but not to HIV can often be selectively restored by IL-2 ( Figs. 3  and 4 ; references 5, 9, and 15). Lymphocytes from nearly all AIDS patients and from some other HIV-infected individuals are, however, unable to proliferate in response to any recall antigens, and these responses cannot generally be reconstituted with IL-2 (4, 5, 15). In the early stages of HIV infection, selective defects in cell-mediated immune responses to HIV antigens may allow infection of susceptible cells by HIV. As more helper T cells are destroyed or inhibited by HIV in the course of infection these defects become nonselective, and eventually in AIDS these patients lose the ability of their lymphocytes to proliferate in response to any antigen (4, 5). These observations suggest that the ability of HIV to remain immunologically cryptic with respect to lymphocyte proliferation is an important factor in the pathobiology of HIV infections. Recombinant envelope (ENV2-3) and core (p25) proteins of HIV (10, 11, 14) were analyzed for their ability to inhibit proliferative responses to TT or PHA as described in Methods. The cpm and SI of [3Hlthymidine incorporated are reported.
The results presented in this report and elsewhere (9, 15, 29) demonstrate that at least some HIV-infected individuals can manifest lymphocyte proliferative responses to HIV or its subunits. In our studies ( Fig. 1 and reference 9 ) only one individual has been detected whose lymphocytes proliferated in response to whole purified HIV. The reproducible abrogation of this response by rIL-2 may be attributable to rIL-2-induced alteration of the kinetics of proliferation or to enhancement of HIV replication by cellular activation (31) . Longitudinal studies of responders to HIV or its subunits indicate that these responses are transient in nature (unpublished observations). Studies by Zagury and colleagues also indicate that even in an HIV Ab-individual who was inoculated with an HIV vaccine, in vitro proliferative responses to HIV were only detectable for a few months after primary or subsequent immunizations (32 (Table I ). This finding suggests that the sugar residues of gpl 20 may be important in its biological effects either by direct interaction of these sugars with CD4 or by maintaining functionally important molecular conformations of gp 120 epitopes. Additional studies directly comparing glycosylated and nonglycosylated forms of the external envelope glycoproteins of HIV-SF2 and other isolates are necessary to confirm and elucidate the roles of carbohydrates in gpl 20-mediated suppression of lymphocyte proliferation.
The studies in this report demonstrate that HIV infections, unlike those of CMV or influenza (5, 9, 27), do not usually induce long-lasting lymphocytes capable of proliferating in vitro in response to the cognate viral antigens. Additional analysis of methods to effectively stimulate cell-mediated responses to HIV antigens may have important applications in the design of vaccines and immunotherapy for HIV infections. Nonglycosylated HIV envelope proteins or synthetic peptide subunits may overcome the potential problems associated with the use of an immunosuppressive gpl 20 moiety in prophylactic or therapeutic AIDS vaccines.
